{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:30:27Z","timestamp":1789752627055,"version":"4.0.1"},"reference-count":26,"publisher":"American Diabetes Association","issue":"8","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,8,1]]},"abstract":"<jats:p>OBJECTIVE\u2014To describe the direct medical costs associated with type 2 diabetes, as well as its treatments, complications, and comorbidities.<\/jats:p>\n               <jats:p>RESEARCH DESIGN AND METHODS\u2014We studied a random sample of 1,364 subjects with type 2 diabetes who were members of a Michigan health maintenance organization. Demographic characteristics, duration of diabetes, diabetes treatments, glycemic control, complications, and comorbidities were assessed by surveys and medical chart reviews. Annual resource utilization and costs were assessed using health insurance claims. The log-transformed annual direct medical costs were fitted by multiple linear regression to indicator variables for demographics, treatments, glycemic control, complications, and comorbidities.<\/jats:p>\n               <jats:p>RESULTS\u2014The median annual direct medical costs for subjects with diet-controlled type 2 diabetes, BMI 30 kg\/m2, and no microvascular, neuropathic, or cardiovascular complications were $1,700 for white men and $2,100 for white women. A 10-kg\/m2 increase in BMI, treatment with oral antidiabetic or antihypertensive agents, diabetic kidney disease, cerebrovascular disease, and peripheral vascular disease were each associated with 10\u201330% increases in cost. Insulin treatment, angina, and MI were each associated with 60\u201390% increases in cost. Dialysis was associated with an 11-fold increase in cost.<\/jats:p>\n               <jats:p>CONCLUSIONS\u2014Insulin treatment and diabetes complications have a substantial impact on the direct medical costs of type 2 diabetes. The estimates presented in this model may be used to analyze the cost-effectiveness of interventions for type 2 diabetes.<\/jats:p>","DOI":"10.2337\/diacare.26.8.2300","type":"journal-article","created":{"date-parts":[[2007,3,5]],"date-time":"2007-03-05T22:51:27Z","timestamp":1173135087000},"page":"2300-2304","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":206,"title":["The Direct Medical Cost of Type 2 Diabetes"],"prefix":"10.2337","volume":"26","author":[{"given":"Michael","family":"Brandle","sequence":"first","affiliation":[{"name":"Division of Endocrinology & Metabolism, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honghong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Michigan, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara R.K.","family":"Smith","sequence":"additional","affiliation":[{"name":"Division of Endocrinology & Metabolism, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanna","family":"Marriott","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Michigan, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray","family":"Burke","sequence":"additional","affiliation":[{"name":"Division of Endocrinology & Metabolism, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan"},{"name":"Michigan Diabetes Research and Training Center, University of Michigan, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahman P.","family":"Tabaei","sequence":"additional","affiliation":[{"name":"Division of Endocrinology & Metabolism, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan"},{"name":"Michigan Diabetes Research and Training Center, University of Michigan, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morton B.","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Michigan, Ann Arbor, Michigan"},{"name":"Michigan Diabetes Research and Training Center, University of Michigan, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Herman","sequence":"additional","affiliation":[{"name":"Division of Endocrinology & Metabolism, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan"},{"name":"Department of Epidemiology, University of Michigan, Ann Arbor, Michigan"},{"name":"Michigan Diabetes Research and Training Center, University of Michigan, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","reference":[{"key":"2022031215280399600_R1","doi-asserted-by":"crossref","unstructured":"King H, Aubert RE, Herman WH: Global burden of diabetes, 1995\u20132025: prevalence, numerical estimates, and projections. Diabetes Care\u200821: 1414\u20131431, 1998","DOI":"10.2337\/diacare.21.9.1414"},{"key":"2022031215280399600_R2","doi-asserted-by":"crossref","unstructured":"Caro JJ, Ward AJ, O\u2019Brien JA: Lifetime costs of complications resulting from type 2 diabetes in the U.S. Diabetes Care\u200825:476\u2013481, 2002","DOI":"10.2337\/diacare.25.3.476"},{"key":"2022031215280399600_R3","unstructured":"American Diabetes Association: Direct and Indirect Costs of Diabetes in the United States in 1992. Alexandria, VA, American Diabetes Association, 1993"},{"key":"2022031215280399600_R4","doi-asserted-by":"crossref","unstructured":"Rubin RJ, Altman WM, Mendelson DN: Health care expenditures for people with diabetes mellitus, 1992. J Clin Endocrinol Metab\u200878:809A\u2013809F, 1994","DOI":"10.1210\/jcem.78.4.8157701"},{"key":"2022031215280399600_R5","doi-asserted-by":"crossref","unstructured":"Pagano E, Brunetti M, Tediosi F, Garattini L: Costs of diabetes: a methodological analysis of the literature. Pharmacoeconomics\u200815:583\u2013595, 1999","DOI":"10.2165\/00019053-199915060-00006"},{"key":"2022031215280399600_R6","doi-asserted-by":"crossref","unstructured":"Huse DM, Oster G, Killen AR, Lacy MJ, Colditz GA: The economic cost of non-insulin dependent diabetes mellitus. JAMA\u2008262:2708\u20132713, 1989","DOI":"10.1001\/jama.262.19.2708"},{"key":"2022031215280399600_R7","doi-asserted-by":"crossref","unstructured":"Selby JV, Ray GT, Zhang D, Colby CJ: Excess costs of medical care for patients with diabetes in a managed care population. Diabetes Care\u200820:1396\u20131402, 1997","DOI":"10.2337\/diacare.20.9.1396"},{"key":"2022031215280399600_R8","doi-asserted-by":"crossref","unstructured":"Brown JB, Nichols GA, Glauber HS, Bakst AW: Type 2 diabetes: incremental medical care costs during the first 8 years after diagnosis. Diabetes Care\u200822:1116\u20131124, 1999","DOI":"10.2337\/diacare.22.7.1116"},{"key":"2022031215280399600_R9","doi-asserted-by":"crossref","unstructured":"Donnan PT, Leese GP, Morris AD: Hospitalizations for people with type 1 and type 2 diabetes compared with the nondiabetic population of Tayside, Scotland: a retrospective cohort study of resource use. Diabetes Care\u200823:1774\u20131779, 2000","DOI":"10.2337\/diacare.23.12.1774"},{"key":"2022031215280399600_R10","doi-asserted-by":"crossref","unstructured":"Jonsson PM, Marke LA, Nystrom L, Wall S, Ostman J: Excess costs of medical care 1 and 8 years after diagnosis of diabetes: estimates from young and middle-aged incidence cohorts in Sweden. Diabetes Res Clin Pract\u200850:35\u201347, 2000","DOI":"10.1016\/S0168-8227(00)00161-3"},{"key":"2022031215280399600_R11","doi-asserted-by":"crossref","unstructured":"O\u2019Brien JA, Shomphe LA, Kavanagh PL, Raggio G, Caro JJ: Direct medical costs of complications resulting from type 2 diabetes in the U.S. Diabetes Care\u200821:1122\u20131128, 1998","DOI":"10.2337\/diacare.21.7.1122"},{"key":"2022031215280399600_R12","doi-asserted-by":"crossref","unstructured":"Glauber HS, Brown JB: Impact of cardiovascular disease on health care utilization in a defined diabetic population. J Clin Epidemiol\u200847:1133\u20131142, 1994","DOI":"10.1016\/0895-4356(94)90100-7"},{"key":"2022031215280399600_R13","doi-asserted-by":"crossref","unstructured":"Brown JB, Pedula KL, Bakst AW: The progressive cost of complications in type 2 diabetes mellitus. Arch Intern Med\u2008159:1873\u20131880, 1999","DOI":"10.1001\/archinte.159.16.1873"},{"key":"2022031215280399600_R14","doi-asserted-by":"crossref","unstructured":"Ramsey SD, Newton K, Blough D, McCulloch DK, Sandhu N, Wagner EH: Patient-level estimates of the cost of complications in diabetes in a managed-care population. Pharmacoeconomics\u200816:285\u2013295, 1999","DOI":"10.2165\/00019053-199916030-00005"},{"key":"2022031215280399600_R15","doi-asserted-by":"crossref","unstructured":"Redekop WK, Koopmanschap MA, Rutten GE, Wolffenbuttel BH, Stolk RP, Niessen LW: Resource consumption and costs in Dutch patients with type 2 diabetes mellitus: results from 29 general practices. Diabet Med\u200819:246\u2013253, 2002","DOI":"10.1046\/j.1464-5491.2002.00654.x"},{"key":"2022031215280399600_R16","doi-asserted-by":"crossref","unstructured":"Henriksson F, Agardh CD, Berne C, Bolinder J, Lonnqvist F, Stenstrom P, Ostenson CG, Jonsson B: Direct medical costs for patients with type 2 diabetes in Sweden. J Intern Med\u2008248:387\u2013396, 2000","DOI":"10.1046\/j.1365-2796.2000.00749.x"},{"key":"2022031215280399600_R17","doi-asserted-by":"crossref","unstructured":"The Diabetes Control and Complications Trial Research Group: Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. JAMA\u2008276:1409\u20131415, 1996","DOI":"10.1001\/jama.276.17.1409"},{"key":"2022031215280399600_R18","doi-asserted-by":"crossref","unstructured":"Eastman RC, Javitt JC, Herman WH, Dasbach EJ, Zbrozek AS, Dong F, Manninen D, Garfield SA, Copley-Merriman C, Maier W, Eastman JF, Kotsanos J, Cowie CC, Harris M: Model of complications of NIDDM. I. Model construction and assumptions. Diabetes Care\u200820:725\u2013734, 1997","DOI":"10.2337\/diacare.20.5.725"},{"key":"2022031215280399600_R19","doi-asserted-by":"crossref","unstructured":"Eastman RC, Javitt JC, Herman WH, Dasbach EJ, Copley-Merriman C, Maier W, Dong F, Manninen D, Zbrozek AS, Kotsanos J, Garfield SA, Harris M: Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care\u200820:735\u2013744, 1997","DOI":"10.2337\/diacare.20.5.735"},{"key":"2022031215280399600_R20","doi-asserted-by":"crossref","unstructured":"The CDC Diabetes Cost-effectiveness Group: Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA\u2008287:2542\u20132551, 2002","DOI":"10.1001\/jama.287.19.2542"},{"key":"2022031215280399600_R21","doi-asserted-by":"crossref","unstructured":"Bagust A, Hopkinson PK, Maier W, Currie CJ: An economic model of the long-term health care burden of type II diabetes. Diabetologia\u200844:2140\u20132155, 2001","DOI":"10.1007\/s001250100023"},{"key":"2022031215280399600_R22","doi-asserted-by":"crossref","unstructured":"The TRIAD Study Group: The Translating Research Into Action for Diabetes (TRIAD) study: a multicenter study of diabetes in managed care (Review Article). Diabetes Care\u200825:386\u2013389, 2002","DOI":"10.2337\/diacare.25.2.386"},{"key":"2022031215280399600_R23","doi-asserted-by":"crossref","unstructured":"Nichols GA, Brown JB: The impact of cardiovascular disease on medical care costs in subjects with and without type 2 diabetes. Diabetes Care\u200825:482\u2013486, 2002","DOI":"10.2337\/diacare.25.3.482"},{"key":"2022031215280399600_R24","unstructured":"Dong FB, Manninen DL, Dasbach EJ, Carides GW, Herman WH, Collins AJ: The longitudinal cost of end-stage renal disease in persons with diabetes in the United States (Abstract). Diabetes\u200851 (Suppl. 2):A272, 2002"},{"key":"2022031215280399600_R25","doi-asserted-by":"crossref","unstructured":"Krop JS, Saudek CD, Weller WE, Powe NR, Shaffer T, Anderson GF: Predicting expenditures for Medicare beneficiaries with diabetes: a prospective cohort study from 1994 to 1996. Diabetes Care\u200822:1660\u20131666, 1999","DOI":"10.2337\/diacare.22.10.1660"},{"key":"2022031215280399600_R26","doi-asserted-by":"crossref","unstructured":"Wagner EH, Sandhu N, Newton KM, McCulloch DK, Ramsey SD, Grothaus LC: Effect of improved glycemic control on health care costs and utilization. JAMA\u2008285:182\u2013189, 2001","DOI":"10.1001\/jama.285.2.182"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/26\/8\/2300\/660921\/dc0803002300.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/26\/8\/2300\/660921\/dc0803002300.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T15:30:52Z","timestamp":1647099052000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/26\/8\/2300\/22704\/The-Direct-Medical-Cost-of-Type-2-Diabetes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,8,1]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2003,8,1]]}},"URL":"https:\/\/doi.org\/10.2337\/diacare.26.8.2300","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,8,1]]}}}